← Leaderboards
Gerald Krueger
University Of Utah
$898,699
Attributed
$898,699
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$5,547,985 · 7
By mechanism
P01$5,245,524 · 2
M01$302,461 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Utah
Same institution · by research overlap
- Jeffrey R Morgan$2,250,746
- Peter J Stang$4,578,295
- J Krueger$1,624
- Thomas M McIntyre$16,430,367
- Lisa A. Cannon Albright$14,179,490
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPsoriasisClinical ResearchGenetic TransductionNonhuman Therapy EvaluationHuman Therapy EvaluationDosageSkin TransplantationGene TherapyGenetic DisorderDrug Screening /EvaluationLeukocyte Adhesion MoleculesImmunotherapySkin Disorder ChemotherapyImmunoglobulin GChimeric ProteinsAthymic MouseCell SenescenceExtracellular MatrixFibroblastsGene ExpressionGene Induction /RepressionGenetic ManipulationHuman Tissue
Grant awards (16)
UTAH PSORIASIS INITIATIVE$4,194
M01 · FY2005 · RR
Utah psoriasis initiative$43,683
M01 · FY2004 · RR
USE OF GENETICALLY MODIFIED SKIN TO TREAT DISEASE$1,209,926
P01 · FY2003 · HD
USE OF GENETICALLY MODIFIED SKIN TO TREAT DISEASE$1,181,915
P01 · FY2002 · HD
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN$204,124
P01 · FY2002 · HD
DOSE RESPONSE STUDY OF BG9273(LFA 3 &IGG1 FUSION PROTEIN)$0
M01 · FY2002 · RR
USE OF GENETICALLY MODIFIED SKIN TO TREAT DISEASE$1,135,180
P01 · FY2001 · HD
DOSE RESPONSE STUDY OF BG9273(LFA 3 &IGG1 FUSION PROTEIN)$248,088
M01 · FY2001 · RR
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN$204,124
P01 · FY2001 · HD
FIVE DOSE TRIAL OF ABX IL8 IN TREATMENT OF SEVERE PLAQUE PSORIASIS$1,624
M01 · FY2001 · RR
RANDOMIZED DOUBLE BLIND STUDY TO EVALUATE BIOLOGIC ACTIVITY OF BG9273$1,624
M01 · FY2001 · RR
DOSE RESPONSE STUDY OF BG9273(LFA 3 &IGG1 FUSION PROTEIN)$1,624
M01 · FY2001 · RR
DOSE RESPONSE STUDY OF BG9273(LFA 3 &IGG1 FUSION PROTEIN)$0
M01 · FY2001 · RR
USE OF GENETICALLY MODIFIED SKIN TO TREAT DISEASE$1,122,265
P01 · FY2000 · HD
APPROACHES TO CORRECT DISEASES WITH GENETICALLY MODIFIED CELLS OF THE SKIN$187,990
P01 · FY2000 · HD
DOSE RESPONSE STUDY OF BG9273(LFA 3 &IGG1 FUSION PROTEIN)$1,624
M01 · FY2000 · RR